European Medicines Agency Approves Modification to Paediatric Investigation Plan for Agamree and Vamorolone

Summary

The European Medicines Agency has made a decision on a modification to the Paediatric Investigation Plan (PIP) for Agamree and vamorolone, a treatment for congenital, familial, and genetic disorders, following an application for change to the existing plan.